Patent classifications
C12Y205/01006
S-adenosylmethionine synthetase expression elements identified from Arabidopis thaliana
The present invention provides non-coding regulatory element polynucleotide molecules isolated from the S-adenosyl methionine synthetase (SAMS3) gene of Arabidopsis thaliana and useful for expressing transgenes in plants. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the Arabidopsis thaliana regulatory polynucleotide sequences, and methods for preparing and using the same.
Microbial cells for spermidine production
The present invention generally related to a modified microbial cell capable of producing high levels of spermidine and/spermidine derivatives. The genetically modified microbial cell comprises at least one modification to native spermidine biosynthetic pathway via putrescine together with genes involved in the S-adenosylmethionine biosyntheticpathway.
ENGINEERING NEW METABOLIC PATHWAYS IN ISOLATED CELLS FOR THE DEGRADATION OF GUANIDINOACETIC ACID AND SIMULTANEOUS PRODUCTION OF CREATINE
The present invention relates to an isolated cell modified for catalyzing the conversion of guanidinoacetate acid (GAA) into creatine in the presence of glucose and methionine using an exogenous guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) protein, a pharmaceutical composition comprising a plurality of said isolated cells and uses thereof.
Modified host cells for high efficiency production of vanillin
Provided herein are genetically modified host cells, compositions, and methods for improved production of vanillin and/or glucovanillin. The host cells, compositions, and methods described herein provide an efficient route for the heterologous production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
Target to treat a metabolic disease in an individual
Provided herein are methods, compounds, and compositions for reducing expression of MAT1a in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual.